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Survivin is a multifunctional protein with essential roles in
cell division and inhibition of apoptosis, but the molecular
underpinnings of its cytoprotective properties are poorly under-
stood. Here we show that homozygous deletion of the aryl
hydrocarbon receptor-interacting protein (AIP), a survivin-as-
sociated immunophilin, causes embryonic lethality in mice by
embryonic day 13.5–14, increased apoptosis of Ter119/
CD71 early erythropoietic progenitors, and loss of survivin
expression in its cytosolic and mitochondrial compartments in
vivo. In import assays using recombinant proteins, AIP directly
mediated the import of survivin to mitochondria, thus enabling
its anti-apoptotic function, whereas a survivin 1–141 mutant
that does not bind AIP was not imported to mitochondria and
failed to inhibit apoptosis. AIP-directed mitochondrial import
of survivin did not affect cell division, was independent of the
organelle transmembrane potential, did not require the chaper-
one Heat Shock Protein 90 (Hsp90), and was inhibited by cyto-
solic factor(s) present in normal cells. shRNA knockdown of the
mitochondrial import receptorTom20abolishedmitochondrial
import of survivin and sensitized tumor cells to apoptosis,
whereas silencing of Tom70 had no effect. Therefore, an AIP-
Tom20 recognition contributes to cell survival in development
and cancer by mediating the mitochondrial import of survivin.
Members of the inhibitor of apoptosis (IAP)3 gene family are
multifunctional proteins (1) that participate in cell survival, cell
proliferation, and a plethora of signal transduction pathways
(2). These properties are commonly exploited in cancer (2),
where aberrant IAP expression is frequently associated with
deregulated cell survival (3), resistance to conventional or tar-
geted therapies (4), and enhanced metastatic dissemination in
vivo (5). This phenotype is exemplified by survivin (6), an IAP
with essential roles in cell division and inhibition of apoptosis
aberrantly overexpressed in virtually every human tumor in
vivo (7). Although it is still unclear which of the twomain func-
tions of survivin is predominantly exploited in cancer, evidence
from transgenicmodels points to a pivotal role of survivin cyto-
protection in the growth of epithelial (8) and hematopoietic (9)
malignancies, potentially via deregulation of stem cell-like
compartment(s) in vivo (10).
As far as mechanistic requirements, recent evidence has
implicated a pool of survivin localized to mitochondria as spe-
cifically earmarked to inhibit apoptosis (11). Several models
have been proposed as to how mitochondrial survivin may
function in cytoprotection, including sequestration of proapo-
ptotic Smac (12), inhibition of its release from mitochondria
(13), or, alternatively, assembly of a phosphorylation-regulated
complex with X-chromosome-linked inhibitor of apoptosis
protein (XIAP) in the cytosol (14) that enhances XIAP stability
and synergistically inhibits caspases (14, 15). Although a mito-
chondrial pool of survivin has been almost exclusively detected
in tumor, as opposed to normal cells (11), and directly linked to
disease progression in vivo (14), survivin lacks a recognizable
mitochondrial import sequence, and the molecular underpin-
nings of its localization to mitochondria, and thus anti-apop-
totic functions, have not been elucidated.
Preprotein import tomitochondria is a stepwise process that
involves the translocase of outer membrane (TOM) complex
located on the outer mitochondrial membrane (16, 17). The
TOM complex contains at least seven subunits, including
Tom40, 22, 7, 6, and 5 and two major receptor molecules,
Tom20 and Tom70 (18). Reconstitution experiments of mito-
chondrial import reactions in vitro have led to a workingmodel
in which Tom70 recognizes preproteins with an internal mito-
chondrial targeting signal, in a process contributed by cytosolic
chaperones, including Hsp70 and Hsp90 (19). Conversely, pre-
proteins containing an amino-terminal, cleavable mitochon-
drial targeting sequence are preferentially translocated via the
Tom20 receptor, with the cytosolic immunophilin, aryl hydro-
carbon receptor-interacting protein (AIP, also called XAP-2)
(20, 21) assisting in this process (22). Intriguingly, biochemical
evidence indicates that survivin associates with Hsp90 (23) as
well as AIP (24) through non-overlapping recognition sites.
Although these interactions have been linked to enhanced sur-
vivin stability against proteasomal degradation in vivo (23, 24),
their potential role in subcellular trafficking, including mito-
chondrial localization, has not been determined.
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In this study, we investigated mechanisms of survivin local-
ization tomitochondria and their potential impact on apoptosis
inhibition, especially in tumors. We found that an AIP-Tom20
recognition provides for the main mechanism of survivin
import to mitochondria and that this pathway exerts an essen-
tial prosurvival role during erythropoietic development in vivo.
EXPERIMENTAL PROCEDURES
Cell Lines and Antibodies—AnAIP gene-trapped embryonic
stem cell line, RRI002, was obtained from the Mutant Mouse
Regional Resource Center. RRI002 cells contain a disrupted
AIP locus in which a -galactosidase reporter gene substitutes
the last COOH terminus 300 amino acids of AIP. In RRI002
cells, the inserted -galactosidase gene is expressed under the
control of the endogenous AIP promoter. Cervical carcinoma
HeLa, breast adenocarcinoma MCF-7, and human embryonic
kidney HEK293T cells were obtained from the ATCC and
maintained in culture as recommended by the supplier. Anti-
bodies against AIP (Novus Biologicals), survivin (Novus Biolog-
icals), Tom20 (Santa Cruz Biotechnology), Tom70 (Novus Bio-
logicals), COX-IV (Clontech), Smac (Pro-Sci), -actin (Sigma),
and Hsp90 (BD Biosciences) were used. The Hsp90 ATPase
inhibitor geldanamycin (GA) was obtained from LC Laborato-
ries (Woburn, MA).
Generation of AIP Knockout Mice—All experiments involv-
ing animals were approved by an Institutional Animal Care and
Use Committee. To generate chimeric AIP knockout mice,
gene-trapped RRI002 embryonic stem cells weremicroinjected
into mouse blastocysts by the Transgenic Animal Modeling
Core at the University of Massachusetts Medical School, and
male chimeric mice were bred with C57Bl/6 female mice. For
genotyping experiments, genomic DNA was isolated from
mouse tail using a DNeasy tissue kit (Qiagen) according to the
manufacturer’s instructions. A primer set comprising AIP-
forward 5-GTTATGTACCACTTCTGCTAGGAGC-3 and
AIP-reverse 5-TGCAGCGTCCGAAAGTGGAA-3 was used
to amplify thewild-typeAIP allele, with generation of a product
of 800 nt (Fig. 1A). A primer set comprising -galactosidase-
reverse 5-CCTCTTCGCTATTACGCCAGC-3 in combina-
tionwith theAIP-forward primerwas used to amplify the gene-
trapped allele with generation of a product of 1000 nt (Fig. 1A).
Amplification reactions were performed using Platinum
TaqDNA polymerase (Invitrogen) according to the manufac-
turer’s instructions. PCR products were separated by electro-
phoresis on 1% agarose gels, stained with ethidium bromide,
and visualized under ultraviolet light. Backcross mating with
C57Bl/6 was performed for more than 10 generations to red-
erive the genetic background.
Plasmid Construction—A cDNA encoding the phosphate
carrier gene (PiC) was purchased from Invitrogen, amplified
with primers 5-AAAAAGGATCCAGGAGGATGTTCTCG-
TCCGTAGC-3 (forward) and 5-AAAAACTCGAGCT-
ACTCAGTTAACCCAAGCTTCTTCTTC-3 (reverse), and
inserted into pcDNA 3.0 (Invitrogen) after digestion with
BamHI and XhoI. A cDNA encoding the mitochondrial
import receptor Tom20 was amplified with primers 5-AAA-
AAGAATTCAGAGCTGGGCTTTCCAAGTTACC-3 (for-
ward) and 5-AAAAACTCGAGTCATTCCACATCATCTT-
CAGCCA-3 (reverse). A cDNA encoding the mitochondrial
import receptor Tom70 was amplified with primers 5-AAAA-
AGAATTCCTTGATAGAGCCCAAGCAGCC-3 (forward)
and 5-AAAAACTCGAGTTATAATGTTGGTGGTTTTAA-
TCCGTA-3 (reverse). The amplified PCR products were
digested with EcoRI and XhoI and directionally inserted in the
pGEX-4T plasmid (Amersham Biosciences). Plasmid con-
structs encoding pGEX-Hsp90 (23), pGEX-Survivin, pGEX-
Survivin 1–141, pcDNA-Survivin, pcDNA Survivin 1–141,
pGEX-AIP, pcDNA-AIP, and pcDNA-Smac-FLAG have been
described previously (24).
Recombinant Protein Expression—BL21-CodonPlus-RIL
Escherichia coli (Stratagene) were transformedwith the various
cDNA constructs in pGEX-4T and grown to A600 0.8, and
recombinant protein expressionwas induced in the presence of
0.2 mM isopropyl 1-thio--D-galactopyranoside (American
Bioanalytical) for 5 h at 30 °C. Cells were harvested by centrifu-
gation at 6000  g for 20 min, and the bacterial pellet was
suspended in 50 mM Tris (pH 7.4), 150 mM NaCl, 5 mMMgCl2,
and 1 mMDTT and lysed by sonication. After removal of insol-
uble material by centrifugation at 15,000 g for 30 min twice,
the resulting soluble fractions were mixed with glutathione-
agarose (Sigma) and incubated for 4 h at 4 °C. Bound proteins
were recovered by centrifugation at 1000  g for 1 min and
washed three times in 50mMTris (pH 7.4), 500mMNaCl, 5mM
MgCl2, and 1 mM DTT. In some experiments, the GST frame
was cleaved from the expressed recombinant protein by incu-
bation with 10 units/ml thrombin (Sigma) for 16 h at 4 °C, fol-
lowed by neutralization in p-aminobenzamidine-agarose
(Sigma) for 1 h at 4 °C twice. Protein concentration was deter-
mined by a protein assay reagent (Bio-Rad) using bovine serum
albumin (Sigma) as a standard.
In Vitro Pull-down and Immunoprecipitation—Glutathione-
agarose beads (Sigma) linked to various recombinant proteins
were incubated in H buffer containing 20 mM Hepes (pH 7.7),
75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl2, 1 mg/ml BSA, and
0.05% Nonidet P-40 for 5 min at 22 °C. Protein A-Sepharose
beads (Amersham Biosciences) were washed in IP buffer con-
taining 50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100,
0.5% Nonidet P-40, plus a protease inhibitor mixture (Roche).
Aliquots of 35S-labeled proteins were produced using a TNT
quick-coupled transcription/translation system (Promega) in
the presence of [35S]methionine (Amersham Biosciences). Cell
extracts were prepared by incubating PBS-washed cells in IP
buffer for 1 h at 4 °C, followed by centrifugation at 13,000  g
for 10 min to remove insoluble material. For pull-down exper-
iments, aliquots of bacterially expressed recombinant proteins,
35S-labeled proteins, or cell extracts were incubated with the
conjugated beads for 16 h at 4 °C, washed in H-buffer or IP
buffer five times, and then bound material was separated by
SDS gel electrophoresis and analyzed by autoradiography or
Western blotting (24).
Gene Silencing—siRNA CCAUGACAGACGAAGAGAA
targeting AIP was purchased from Dharmacon (characterized
previously (24)). An siRNA directed to Tom20 (ON-TARGET
plus, SMARTpool L-006487-01-0005) was used. shRNA clones
targeting the mitochondrial import receptor Tom20 or Tom70
were derived from a microRNA-adapted shRNA library
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(shRNAmir) and purchased from Open Biosystems. The
shRNA constructs are inserted into the pGIPZ lentiviral vector
containing a GFP reporter gene. For transfection experiments,
control non-targeting siRNA or the various siRNAs were com-
bined with oligofectamine (Invitrogen) in OPTI-MEM I
medium (Invitrogen) according to the manufacturer’s instruc-
tions. Cells were washed in OPTI-MEM I and incubated with
the siRNA/oligofectamine mixture for 4 h, reconstituted with
complete medium containing 10% FBS, and maintained in cul-
ture for an additional 48 h. Plasmid transfections were carried
out using Lipofectamine reagent (Invitrogen) according to the
manufacturer’s instructions. Transfected cultures were con-
firmed for protein expression or knockdown by Western blot-
ting after 24 h and processed for functional experiments.
Generation of Stably Transfected Cell Lines—Wild-type HA-
tagged survivin or HA-tagged survivin 1–141 mutant cDNA
characterized previously (24) was cloned in the BamHI and
XhoI sites of the pcDNA5/FRT/TO plasmid (Invitrogen). Each
expression vector was cotransfected with pOG44 (Invitrogen)
into Flp-In T-Rex-293 cells (Invitrogen) using Lipofectamine
(Invitrogen). Stable cell lines were selected in the presence of 15
g/ml blasticidin plus 200 g/ml hygromycin B, and condi-
tional expression of HA-reactive survivin was determined
after tetracycline induction (Tet-On system), byWestern blot-
ting. To generate cell lines with stable knockdown of Tom20 or
Tom70, plasmid DNA expressing non-targeting or Tom20- or
Tom70-directed shRNA (Open Biosystems) was transfected
into HeLa cells using Lipofectamine. Cultures were selected in
the presence of 4 g/ml puromycin, and individual clones with
high levels of GFP expression by fluorescence microscopy were
characterized for differential silencing of Tom20 or Tom70 by
Western blotting. Independently established clones were pro-
cessed for functional experiments.
Mitochondrial Isolation—HeLa cells were detached by treat-
ment with trypsin/EDTA (Gibco-BRL) and suspended in com-
plete DMEM medium (Gibco-BRL). After centrifugation, the
cell pellets were washed once in ice-cold PBS (pH 7.4), and
mitochondrial and cytosolic fractions were isolated using a
mitochondria isolation kit (Pierce) according to the manufac-
turer’s instructions and as reported in published protocols (14).
In some experiments, mitochondria were isolated from normal
mouse liver or E11 embryos using a mitochondria isolation kit
(Sigma), and samples from normal or tumor cell types were
analyzed for mitochondrial preprotein import (see below).
Mitochondrial Import Assay—In vitromitochondrial import
assayswere performed as described previously (19). Briefly, 35S-
labeled recombinant proteins were diluted in one volume of
MCS buffer containing 500 mM sucrose, 80 mM potassium ace-
tate, 20 mM HEPES-KOH (pH 7.5), 5 mM magnesium acetate,
and two volumes of MC buffer (250 mM sucrose, 80 mM potas-
sium acetate, 20 mM HEPES-KOH (pH 7.5), 5 mM magnesium
acetate). 50 l of diluted 35S-labeled proteins were mixed with
30g of freshly isolatedmitochondria, and the final volumewas
adjusted to 200 l with MC buffer. The import reaction was
continued for 20 min at 30 °C and terminated by cooling of the
samples on ice. Mitochondria were reisolated by centrifuga-
tion, suspended in MC buffer in the presence of 50 g/ml pro-
teinase K for 10min, andmixedwith 1mMPMSF (Calbiochem)
to terminate the proteolytic reaction. Mitochondria were col-
lected by centrifugation, and imported proteins were separated
by SDS gel electrophoresis, followed by autoradiography. In
some experiments, the mitochondrial uncoupler valinomycin
(1 M) or the Hsp90 inhibitor GA (2 M) was added to the
import reaction before analysis of protein import into mito-
chondria. As control, changes in mitochondrial membrane
potential in the presence or absence of valinomycin (15 M)
were analyzed inHeLa cells by JC-1 staining and flow cytometry
and quantified as a decrease in the green/red fluorescence ratio.
Themitochondrial uncoupler carboxyl cyanide 3-chlorophenyl
hydrazone (CCCP, 50 M) was used as a control for these
experiments.
Analysis of Apoptosis—Wild-type (/) or AIP knockout
(/) embryos were harvested at E12.5, and fetal liver cells were
mechanically dissociated by pipetting in Iscove modified Dul-
becco’s medium containing 20% FBS, 2 mM L-glutamine, and
100 M -mercaptoethanol. Single cell suspensions were pre-
pared by filtration through 70-m cell strainers. Reticulocytes
were lysed by brief osmotic shock, and nucleated cells were
counted. Analysis of erythroid differentiation was carried out
by double labeling for the erythroid-specificmarkerTer119 and
non-erythroid CD71 (transferrin receptor) using multipara-
metric flow cytometry as described (25). This protocol identi-
fies several distinct subpopulations of erythroid progenitors
prior to the onset of erythropoietin dependence with potential
for formation of erythroid colonies (CFU-e). These cellsmature
into a Ter119/CD71 phenotype comprising erythropoietin-
dependent CFU-e (26). For analysis of cell viability, Ter119-
and CD71-stained fetal liver cells were analyzed for reactivity
with annexin V by flow cytometry. For quantification of apo-
ptosis, AIP/ or AIP/ fetal liver cell populations were ana-
lyzed by dual color labeling for annexin V/DAPI and multipa-
rametric flow cytometry. Alternatively, wild-type (/),
heterozygous (/), or knockout (/) AIP embryos were col-
lected at E11, subcellularly fractionated inmitochondrial (5g)
and cytosolic (30g) extracts, and analyzed for differential pro-
tein expression by Western blotting. In other experiments,
HEK293T cells stably transfectedwith wild-type survivin or the
survivin 1–141 truncatedmutant were stimulatedwith 2g/ml
Tet to induce the expression of the various recombinant pro-
teins, incubated with increasing concentrations of taxol (0–1
M, Sigma) for 24 h, and analyzed for changes in cell viability by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
as described. Alternatively, HeLa cells carrying stable shRNA
knockdown of Tom20 or Tom70 were treated with the broad-
spectrum apoptotic stimulus staurosporine (0.5 M) and ana-
lyzed for cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide after 24 h.
ImmunofluorescenceMicroscopy—HEK293T stable transfec-
tants were incubated with Tet to induce the expression of HA-
tagged survivin or the survivin 1–141 mutant. Cells were
washed in PBS (pH 7.4) and fixed in 4% paraformaldehyde for
10min at 22 °C. After permeabilization with 0.1%Triton X-100
in PBS (pH 7.4) for 5 min, cells were blocked in 3% BSA in PBS
containing 0.2% Tween 20 for 1 h at 22 °C and incubated with
an antibody to -tubulin (Sigma) for 18 h at 4 °C. After washes,
cells were incubated with Alexa Fluor 594-conjugated second-
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ary anti-mouse reagent (Molecular Probes), followed by Alexa
Fluor 488-labeled antibody toHA, and analyzed on anAxioplan
2 fluorescence microscope (Zeiss). Images were processed
using Photoshop CS2.
Statistical Analysis—Datawere analyzed using the unpaired t
test on a GraphPad software package forWindows (Prism 4.0).
A p value of 0.05 was considered as statistically significant.
RESULTS
AIP Regulation of Cell Survival in Vivo—Webegan this study
by investigating a potential developmental role of AIP in tissue
integrity in vivo. For these experiments, we generated AIP
knockout mice (27, 28) using gene-trap technology in which a
-galactosidase gene inserted in the AIP locus disrupts the
entire coding sequence of AIP downstream of exon 2 (Fig. 1A).
In genotyping experiments (Fig. 1B), PCR products of 800 nt or,
conversely, 1000 nt, uniquely identified the wild-type AIP allele
or the -galactosidase-containing disrupted allele, respectively
(Fig. 1B). Consistent with the expression of -galactosidase
under the control of the endogenous AIP promoter, AIP/
embryos strongly stained for -galactosidase expression by
immunohistochemistry (Fig. 1C). In agreement with recent
findings (27, 28), homozygous deletion of AIP was embryonic
lethal, with loss of viability andmorphologic involution of 100%
of AIP/ embryos by E13.5–14 (Fig. 1D). Additional features
of AIP/ embryos examined at E12.5 included decreased vas-
cular structures in the yolk sac, reduced liver size, and frequent
hemorrhages (Fig. 1E). Conversely, mice with heterozygous
deletion of AIP were born at expected rates, were fertile, and
exhibited no changes in overall body weight or blood glucose
levels over a 12-month period, compared with AIP/ mice
(Fig. 1F). At variance with a recent report (28), histologic exam-
ination of brain samples collected fromAIP/mice was unre-
markable, with no evidence of increased incidence of pituitary
tumors, compared with wild-type mice (not shown).
To determinewhether lethality of AIP/ embryoswas asso-
ciated with developmental defects in cell survival, we next
examined fetal liver erythropoiesis using an established mul-
tiparametric flow cytometry protocol that quantifies the differ-
ential expression of CD71 and Ter119 markers in erythroblast
populations at progressive stages of differentiation (26). Com-
pared with wild-type liver cells, AIP/ embryos exhibited a
significant decrease in the more differentiated erythroblast
populations, characterized by de novo expression of Ter119
(29) (Fig. 2A). Consequently, AIP/ liver cells were enriched
in the more primitive, Ter119 erythroblast populations (Fig.
FIGURE 1.Characterization of AIP knockout embryos. A, disruption of the AIP locus by gene trapping. The position of coding, non-coding, and untranslated
regions in the AIP gene, and the position of the -galactosidase gene insertion in the AIP locus are shown. The position and orientation of the various primers
(AIP-forward (A-f), AIP-reverse (A-r), and -galactosidase-reverse (-r)) utilized for genotyping is indicated. B, PCR genotyping of AIP/, AIP/, and AIP/
mice. KO, knockout; WT, wild type. C, -galactosidase staining and PCR analysis of the indicated AIP mouse genotypes. D, morphology of AIP/ or AIP/
embryos at the indicated gestational age (E). E, hemorrhages in AIP/ embryos at E12.5. F, wild-type (/) or AIP/ mice were monitored for changes in
overall bodyweight or bloodglucose concentrations at the indicated time intervals. Data aremean S.E. of individual animal groups (weight analysis, AIP/,
n 11; AIP/, n 22; glucose level analysis, AIP/, n 5; AIP/, n 9).
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2A), retaining CFU-e ability (29). To determine whether the
block in erythroblast differentiation observed in AIP/
embryos was due to defective cell survival, we next carried out
annexin V staining of differentiating liver cell populations. In
these experiments, primitive Ter119/CD71 erythroblasts
from AIP/ embryos exhibited considerably increased reac-
tivity for annexin V by flow cytometry, compared with their
wild-type counterparts (Fig. 2B). In addition, Ter119/CD71
erythroid populations, which are highly dependent on erythro-
poietin as a survival factor, remained intensely annexin V-pos-
itive in AIP/ embryos by flow cytometry (Fig. 2B, p 
0.0032). To independently validate genuine induction of
apoptosis under these conditions, we next performed dual
labeling experiments for annexin V andDAPI analyzed bymul-
tiparametric flow cytometry. Consistent with the data reported
above, AIP/ fetal liver cells exhibited increased apoptosis,
compared with wild-type populations (Fig. 2C), with a higher
number of annexin V-positive cells, regardless of DAPI reactiv-
ity (Fig. 2D). Finally, we asked whether the loss of erythroblast
populations in AIP/ embryos solely reflected increased apo-
ptosis (Fig. 2, B–D) or was also potentially contributed by cell
cycle defects. In these experiments, the ratio between CD71/
CD71 liver cells was indistinguishable in wild-type or AIP/
embryos (Fig. 2E), arguing against potential defective cell cycle
transitions in these settings (26).
BecauseAIP functions as a regulator of survivin (24), which is
required for erythropoiesis in vivo (30), we next looked at
potential differences in survivin levels and/or subcellular distri-
bution in AIP/ embryos. Compared with wild-type or
heterozygous embryos, homozygous deletion of AIP at E11
resulted in a nearly complete loss of survivin protein expression
in both its cytosolic and mitochondrial subcellular compart-
ments byWestern blotting (Fig. 2F). Conversely, the embryonic
levels of another mitochondrial protein, Smac, were not
affected in the presence or absence of AIP in E11 embryos
(Fig. 2F).
AIP Is Required for Mitochondrial Import of Survivin—
Transfection of breast adenocarcinomaMCF-7 cells with AIP-
directed siRNA (24) significantly reduced the expression of
endogenous AIP in both mitochondrial and cytosolic fractions
(Fig. 3A). Consistent with the results obtained with AIP/
embryos, this was associated with a nearly complete loss of
survivin expression in its mitochondrial compartment and sig-
nificant reduction of cytoplasmic levels (Fig. 3A). In contrast, a
FIGURE 2.Developmental regulationof apoptosis byAIP.A, fetal liver cells
isolated from AIP/ or AIP/ embryos at E12.5 were analyzed for simulta-
neous expression of CD71 and Ter119 by multiparametric flow cytometry.
B, Ter119/CD71 or Ter119/CD71 fetal liver cell populations isolated
fromAIP/orAIP/embryoswereanalyzed for annexinV reactivityby flow
cytometry. The percentage of annexin V-positive cells is indicated. C, fetal
liver cells isolated from AIP/ or AIP/ embryos were double-labeled for
Annexin V/DAPI and analyzed by multiparametric flow cytometry. For A and
C, the percentage of cells in each quadrant is indicated. D, quantification of
annexin V reactivity in wild-type (AIP/) or AIP/ fetal liver cells. Data are
mean S.E. of replicates of a representative experiment of at least two inde-
pendent determinations. p 0.029 (DAPI negative); p 0.05 (DAPI-positive).
E, fetal liver populations from the indicated AIP genotypes were analyzed for
CD71/CD71 ratio by flow cytometry. F, mitochondria or cytosolic extracts
were isolated from E11 AIP/, AIP/, or AIP/ embryos and analyzed by
Western blotting.
FIGURE 3. AIP regulation of mitochondrial import of survivin. A, MCF-7
cells transfected with control non-targeting (Ctrl) or AIP-directed siRNA were
fractionated in mitochondrial (M) or cytosolic (C) fractions and analyzed by
Western blotting. COX-IV or -actin was used as a mitochondrial or cytosolic
marker, respectively. B, HA-tagged wild-type survivin or the survivin 1–141
mutant was transfected in MCF-7 cells, and mitochondrial or cytosolic frac-
tions were analyzed by Western blotting. C, liver mitochondrial import of
35S-PiC, 35S-survivin, or 35S-Smac was evaluated in the presence () or
absence (-) of the mitochondrial uncoupler valinomycin (val) and quantified
by autoradiography (top panel). Bottom panel, effect of the mitochondrial
uncouplers valinomycin or carboxyl cyanide 3-chlorophenyl hydrazone
(CCCP) onmitochondrialmembrane potential as determinedby JC-1 staining
and flowcytometry. The ratio between JC-1green fluorescence/JC-1 red fluo-
rescence is indicated per each condition tested. D, 35S-survivin or the 35S-
survivin 1–141 mutant was analyzed for import in isolated mitochondria in
the presence of recombinant AIP (0.3 nM-0.3 M) (top panel). Bottom panel,
densitometric quantification of radiolabeled protein bands. Representative
experiment of at least three independent determinations.
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control, non-targeting siRNA had no effect on AIP or survivin
levels in mitochondrial or cytosolic fractions (Fig. 3A).
Previous studies have shown that survivin binds AIP via its
last COOH-terminal Asp-142 (24). Accordingly, a survivin
1–141 truncated mutant that does not bind AIP (24) was
undetectable in isolated mitochondria of transfected MCF-7
cells (Fig. 3B). Conversely, the survivin 1–141 mutant accu-
mulated in the cytosol of MCF-7 cells, albeit at lower levels
than full-length survivin (Fig. 3B), consistent with a role of
AIP in promoting survivin stability in vivo (24). In control
experiments, full-length survivin indistinguishably accumu-
lated in mitochondria or cytosolic fractions of transfected
MCF-7 cells (Fig. 3B).
Using amitochondrial import assay in vitro, 35S-survivin was
readily imported in isolated liver mitochondria, in a reaction
unaffected by disruption of the organelle transmembrane
potential using the uncoupler valinomycin (Fig. 3C). Dissipa-
tion of the mitochondrial membrane potential also did not
affect the import of another mitochondrial intermembrane
space protein, Smac, whereas it significantly reduced the mito-
chondrial import of 35S-PiC, used as control for the import
reaction (Fig. 3C). Under these conditions, addition of increas-
ing concentrations of recombinant AIP to the import reaction
dose-dependently enhanced the accumulation of 35S-survivin
in isolated liver mitochondria (Fig. 3D). In contrast, the AIP-
defective survivin 1–141 truncatedmutant exhibited only back-
ground accumulation inmitochondria, in a reaction not further
affected at any concentration of AIP added (Fig. 3D).
Specificity of AIP-directed Mitochondrial Import of Survivin—
Survivin associates with anothermolecular chaperone involved
in mitochondrial preprotein import, i.e. Hsp90 (23), and a role
of this recognition in survivin localization to mitochondria was
investigated next (19). At variance with the data obtained with
AIP, preincubation of HeLa cells with the small molecule
Hsp90 ATPase inhibitor GA, which inhibits preprotein import
through the Tom70 mitochondrial import receptor (19), did
not affect the import of survivin to mitochondria (Fig. 4A). As
control, GA significantly reduced the cytosolic level of Akt, a
prototype Hsp90 client protein (Fig. 4A). Similarly, GA effi-
ciently inhibited the mitochondrial import of 35S-PiC through
the Tom70 receptor (Fig. 4B), consistent with previous obser-
vations (19). Conversely, GA had no effect on the mitochon-
drial import of [35S]survivin (Fig. 4B).
Requirements of AIP-mediated Mitochondrial Import of
Survivin—A potential basis for the differential subcellular
localization of mitochondrial survivin in tumor, as opposed to
normal cells (11), was investigated next. In initial experiments,
AIP was found abundantly expressed and at comparable levels
in all normal tissues as well as examined tumor cell lines (Fig.
4C). Similarly, 35S-survivin was imported indistinguishably in
mitochondria isolated fromnormalmouse liver or B lymphoma
Raji cells (Fig. 4D), arguing against the possibility that organ-
elle-intrinsic properties mediated the differential localization
ofmitochondrial survivin selectively in tumor cells. Conversely,
addition of increasing concentrations of cytosolic extracts from
normal liver to the import reaction inhibited in a dose-depen-
dent manner the accumulation of wild-type survivin in tumor,
i.e. Raji, mitochondria (Fig. 4E). This response was specific, as
comparable concentrations of cytosolic extracts from normal
liver had no effect on the mitochondrial import of 35S-PiC or
35S-Smac (Fig. 4E).
AIP Recognition Does Not Affect Survivin-dependent Mitosis—
Survivin is a multifunctional protein with essential roles in cell
division (31), and a potential participation of AIP in this path-
way was examined next. For these experiments, we generated
HEK293T cells stably transfected with Tet-regulated inducible
expression of HA wild-type survivin or the AIP-defective sur-
vivin 1–141 truncated mutant (24). In control studies, wild-
type or mutant survivin was comparably expressed at similar
levels inHEK293T cells in response toTet stimulation byWest-
ern blotting (Fig. 5A). Consistent with their normal phenotype
(11), transfected HEK293T cells expressed survivin only in
cytosol, with no localization of wild-type or the survivin 1–141
mutant tomitochondria byWestern blotting of isolated subcel-
FIGURE 4. Requirements of AIP-directedmitochondrial import of survivin. A, HeLa cells were treated with () or without (-) 2M GA for 24 h, and aliquots
of isolatedmitochondrial (Mito) or cytosol extracts were analyzed byWestern blotting. Akt was used as a control Hsp90 client protein. B, mitochondrial import
of 35S-survivin or 35S-PiC was evaluated in the absence or presence of GA. C, cytosol fractions isolated from the indicatedmouse tissues (left) or human tumor
cell lines (right) were analyzed byWestern blotting.D, mitochondria fromRaji cells ormouse liverwere incubatedwith 35S-labeled proteins, survivin and Smac,
and mitochondrial import was analyzed by autoradiography. Detection of COX-IV by Western blotting was used to confirm that comparable amount of
mitochondria were applied in the import assay. E, mitochondrial import of the indicated 35S-labeled proteins was determined in the presence of mouse liver
cytosol extracts and autoradiography (left).Markers, molecular size of preproteins and mature proteins. Right, densitometric quantification of protein bands.
Representative experiment of at least two independent determinations.
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lular fractions (Fig. 5B and not shown). Accordingly, Tet-regu-
lated expression of wild-type survivin or the survivin 1–141
mutant did not protect HEK293T transfectants against apopto-
sis induced by the chemotherapeutic agent taxol (Fig. 5C). Con-
versely, wild-type survivin engineered to accumulate in mito-
chondria by conjugation with the cytochrome c organelle
import sequence efficiently inhibited apoptosis in normal cells
(11). Although unable to inhibit apoptosis, wild-type ormutant
survivin indistinguishably associated with mitotic chromo-
somes and polymerized microtubules in Tet-stimulated
HEK293T cultures and comparably supported mitotic transi-
tions at metaphase, anaphase, and telophase by dual color flu-
orescence microscopy (Fig. 5D).
AIP-Tom20-regulated Mitochondrial Import of Survivin—A
potential participation of the mitochondrial preprotein import
machinery in organelle accumulation of survivin was investi-
gated next. Consistent with earlier reports (19), recombinant
Tom70 associated with endogenous Hsp90 but not AIP in cap-
ture assays using isolated mitochondrial extracts in vivo (Fig.
6A). Reciprocally, recombinant Tom20 bound AIP (22),
whereas Hsp90 was unreactive (Fig. 6A). Under these condi-
tions, survivin strongly bound to a Tom20-AIP complex in cap-
ture assays (Fig. 6A). Similarly, survivin immune complexes
precipitated from Raji cell extracts contained coassociated
Tom20 in vivo (Fig. 6B). In these experiments, AIP was
excluded from a survivin-Tom20 complex, suggesting that this
interaction is transient and potentially reversed upon delivery
of survivin to the mitochondrial import machinery in vivo. In
control experiments, only a weak, albeit detectable, interaction
between survivin and aTom70-Hsp90 complexwas observed in
capture assays (Fig. 6A) as well as immunoprecipitation (Fig.
6B). Although recombinantTom20onlyweakly associatedwith
isolated survivin in vitro (Fig. 6C, top panel), addition of
increasing concentrations of recombinant AIP to the binding
reaction resulted in dose-dependent, enhanced association of
survivin to Tom20 (Fig. 6C, top panel). By contrast, the AIP-
defective survivin 1–141mutant only associated with recombi-
nant Tom20 in the absence of AIP, whereas increasing concen-
trations of AIP blocked this interaction (Fig. 6C, top panel),
potentially reflecting competition for the survivin-Tom20
binding site. As a control, recombinant AIP directly bound
Tom20 in vitro (22), and this recognition was unaffected by
increasing concentrations of recombinant survivin (Fig. 6C,
bottom panel). In contrast, GST did not associate with recom-
binant proteins, with or without exogenously addedAIP or sur-
vivin (Fig. 6C).
FIGURE 5. AIP recognition of survivin does not influence mitotic transi-
tions. A, HEK293T cells stably transfected with Tet-inducible full-length sur-
vivin or the survivin 1–141 mutant were induced with Tet and analyzed for
expression of HA-reactivematerial at the indicated time intervals byWestern
blotting. Chloramphenicol acetyltransferase (CAT) was used as a control.
B, mitochondrial (M) or cytosolic (C) extracts were isolated from Tet-induced
HEK293T survivin transfectants and analyzed by Western blotting. Ran and
COX-IV were cytosolic or mitochondrial markers, respectively. C, HEK293T
cells expressing vector, wild-type survivin, or the survivin 1–141mutant were
treatedwith the indicated increasingconcentrationsof taxol andanalyzed for
cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide. Data are mean S.E. of replicates of a representative experiment of at
least two independent determinations. D, stably transfected HEK293T cells
conditionally expressing survivin or survivin 1–141 were analyzed for meta-
phase or telophase transitions by immunofluorescence microscopy with the
indicated antibodies. DNA was stained with DAPI. Merge, image merging
analysis.
FIGURE 6. Tom20 regulation of mitochondrial import of survivin. A, ali-
quots of GST, GST-Tom20, or GST-Tom70 recombinant proteins were mixed
with Raji cell extracts, and bead-bound material was analyzed by Western
blotting. Bottom panel, Coomassie Blue staining of recombinant GST fusion
proteins. B, Raji mitochondrial extract was immunoprecipitated with an anti-
body to survivin or IgG, and proteins in pellets or supernatants (unbound)
were analyzed by Western blotting. C, recombinant wild-type survivin or the
survivin 1–141 mutant and GST-Tom20 beads were mixed with increasing
concentration of recombinant AIP, and bead-bound proteins were analyzed
by Western blotting (top panel). Bottom panel, GST or GST-Tom20 was incu-
bated with recombinant AIP in the presence of increasing concentrations of
survivin (up to 0.4 M), and bound proteins were analyzed by Western blot-
ting. D, independently established clones (#) of HeLa cells stably transfected
with control (Ctrl) or Tom70- or Tom20-directed shRNA were analyzed by
Western blotting. E, HeLa cells were transfected with control, non-targeting
(Ctrl) or Tom20-directed siRNA and analyzed by Western blotting. TCE, total
cell extracts. F, clones of HeLa cells with stable knockdown of Tom70 or
Tom20 were treated with 0.5 M staurosporine for 24 h and analyzed for cell
viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide.
Data aremeanS.E. of replicates (n3). ***,p0.0001. Twodifferent clones
per conditions were tested with identical results in two independent
experiments.
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To further investigate a role of mitochondrial import recep-
tors on survivin cytoprotection, we next generated HeLa cells
with stable knockdown of Tom20 or Tom70 by shRNA.
Tom20- or Tom70-directed shRNA efficiently silenced the
expression of the intended target receptor in two independent
clones analyzed, but not vice versa (Fig. 6D). Under these con-
ditions, stable silencing of Tom20 inhibited the accumulation
of endogenous survivin in HeLa cell mitochondria (Fig. 6D),
further reinforcing a role of an AIP-Tom20 recognition in sur-
vivin mitochondrial import. In contrast, shRNA silencing of
Tom70 did not affect the mitochondrial pool of survivin in
HeLa cells (Fig. 6D). Conversely, siRNA silencing of Tom20 did
not significantly affect the cytosolic pool of survivin in HeLa
cells (Fig. 6E). Functionally, stable shRNA knockdown of
Tom20 sensitized HeLa cells to apoptosis induced by the broad
cell death stimulus staurosporine (Fig. 6F). In contrast, shRNA
silencing of Tom70 or transfection with control, non-targeting
shRNA had no effect on staurosporine-induced apoptosis
(Fig. 6F).
DISCUSSION
In this study, we have shown that the immunophilin AIP (20,
21) is an essential gene in vivo and that its homozygous deletion
in mice causes embryonic lethality at E13.5–14 (27, 28), aber-
rantly enhanced apoptosis during early erythropoietic differen-
tiation, and loss of survivin expression in both its cytosolic and
mitochondrial compartments in vivo. Functionally, AIP
directlymediates themitochondrial import of survivin through
a Tom20- but not Tom70-dependent recognition, thus ena-
bling its anti-apoptotic function in vivo (11).
In addition to its role as a cochaperone stabilizing the aryl
hydrocarbon receptor (32, 33) in the xenobiotic response to
polycyclic aromatic compounds, for instance, 2,3,7,8-tetrachlo-
rodibenzo-p-dioxin or “dioxin” (34), AIP has recently attracted
attention for its potential link to certain types of pituitary ade-
nomas (35). Accordingly, 15% of patients with a rare neu-
roendocrine syndrome called familial isolated pituitary ade-
noma, but not sporadic adenomas (36), have been shown to
harbor a variety of defects in the AIP locus (37), including inac-
tivating germ line mutations as well as large genomic deletions
(38) that disrupt the COOH-terminal of the AIP protein.
Although it is unclear how AIP deficiency in these settings may
contribute to pituitary adenomas (39), the observed loss of
heterozygosity in patients carrying AIP mutant tumors (40),
combined with the reported development of pituitary adeno-
mas inAIP/mice (28), has prompted themodel thatAIPmay
function in an as yet unidentified pathway of neuroendocrine
tumor suppression (41).
Although not ruling out this possibility, the data presented
here point to a more complex scenario for AIP function(s) in
vivo, which includes a novel, developmentally regulated role in
cell survival. In this context, adult-type erythropoiesis becomes
established in the embryo betweenE11.5 andE14 through rapid
expansion of erythroid progenitors in the liver, essential for the
survival of the embryo beyond E13.5 (42). Ter119 erythroid
subsets, which are functionally CFU-e cells, are the most likely
to undergo apoptosis during development, a process counter-
acted by the hormone erythropoietin (25). Our multiparamet-
ric flow cytometry profiling of liver cells from AIP knockout
embryos identified high levels of apoptosis in these immature
CD71/Ter119 erythropoietic progenitors, which may inter-
fere with the required rapid establishment of erythropoiesis at
this stage of development and contribute, at least in part, to the
observed lethal phenotype. Importantly, these cells did not
exhibit changes in the CD71/CD71 ratio, which is sensitive
to defects in cell cycle transitions (26), reaffirming a pivotal role
of increased apoptosis in the observed loss of erythropoietic
progenitors in AIP/ embryos. Other aspects of AIP/
embryos described here appear in broad agreement with previ-
ous reports, reaffirming the invariable embryonic lethality of
homozygous AIP deletion by E14–14.5 and the presence of
extensive vascular defects, potentially because of developmen-
tal abnormalities in blood vessel formation (27, 28). At variance
with a previous report (28), however, we found no significant
increase in pituitary adenomas in heterozygous AIP/ mice,
compared with their wild-type littermates. The reason for this
discrepancy is presently unknown, but potential differences in
genetic background or penetrance of this phenotype may
account for the results.
Although the basis for the essential developmental role of
AIP in vivo remains to be fully elucidated, the data presented
here suggest that at least some aspects of this pathway may be
attributable to regulation of survivin function, especially sub-
cellular localization to mitochondria (11), which is a molecular
prerequisite for survivin cytoprotection in vivo (14). Accord-
ingly, and reminiscent of the phenotype of AIP/ embryos
observed here and in other studies (27, 28), conditional deletion
of the survivin gene in the hematopoietic compartment pro-
duces lethal defects in erythropoiesis with dramatic down-
stream reduction of enucleated erythrocytes (30). This pathway
has been reported as highly evolutionary conserved (43), poten-
tially reflecting exaggerated apoptosis in the absence of survivin
in vivo. Similarly, survivin is essential for proper blood vessel
development, and conditional ablation of the survivin gene in
endothelial cells also results in embryonic lethality, hemor-
rhages, and cardiac malformations (44), similar to the pheno-
type observed for AIP/ embryos (27).
A role for AIP in mitochondrial preprotein import through
the Tom20 import receptor has been proposed previously (22).
In agreement with these findings, the AIP pathway of mito-
chondrial import of survivin described herewas specific forAIP
anddid not involveHsp90, another survivin-binding chaperone
(23) that contributes to mitochondrial preprotein import (19).
In addition, AIP-mediated mitochondrial accumulation of sur-
vivin was not affected by the organelle transmembrane poten-
tial but required the import receptor Tom20, which bound sur-
vivin in a recognition cooperatively favored by AIP. Although it
is unclear which internal sequence(s) in survivin may partici-
pate in organelle targeting (45), the data presented here suggest
an overall model in which AIP binds survivin in the cytosol via
its COOH terminus sequence, EQLAAMD, with the last Asp
residue playing a critical role in the recognition (24). In turn, a
survivin-AIP complex is protected against proteolysis in the
cytosol (24) and directly delivers survivin to the Tom20 mito-
chondrial import machinery (this study) for translocation
across the mitochondrial membrane (22), thus enabling its
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anti-apoptotic function (11). Consistent with this scenario, sta-
ble shRNA knockdown of Tom20, but not Tom70, abolished
survivin import to mitochondria and increased the sensitivity
of tumor cells to apoptosis. This is reminiscent of earlier work
that also implicated Tom20 in cytoprotection by mediating the
insertion of anti-apoptotic Bcl-2 into the mitochondrial outer
membrane (46).
Here, experiments with conditional expression of survivin or
the AIP-defective survivin 1–141 truncated mutant demon-
strated that the AIP-Tom20 recognition is selectively impli-
cated inmitochondrial import of survivin, and thus cytoprotec-
tion (11), whereas it had no effect on the localization of survivin
to themitotic apparatus or its essential roles at cell division (31).
Despite considerable efforts (47), it has been difficult to unam-
biguously discriminate between the two main functions of sur-
vivin in apoptosis inhibition and the regulation of mitosis, and
especially which of these properties is most exploited during
tumorigenesis in vivo (7). As shown here, the selectivity by
which AIP regulates the mitochondrial import of survivin
uniquely marks the function of survivin in cytoprotection, thus
providing a specific mechanism to further probe its require-
ments in development and cancer (7).
Consistentwith this view, one of themost distinctive features
of mitochondrial survivin is its nearly unique expression in
tumor as opposed to normal cells (11), potentially contributing
to resistance to therapy and unfavorable disease outcome (7).
Here, the differential recruitment of survivin to mitochondria
of tumor versus normal cell types (11) was not attributable to
differences in AIP expression, which was ubiquitously present
in normal or transformed cells, or mitochondrial-intrinsic
properties of the tumor type. Conversely, AIP-directed accu-
mulation of survivin in mitochondria was progressively inhib-
ited by cytosolic extracts from normal cells in a pathway that
was specific for survivin, as the import of other mitochondrial
inter-membrane space molecules was not affected. In this con-
text, it is possible that differential binding of survivin to regula-
tory molecules in the cytosol, including chaperones (23), may
further assist in AIP-directed mitochondrial import selectively
in tumor cells, potentially by affecting the availability or recog-
nition of putative survivin organelle targeting sequence(s) (45).
In summary, these data identify a novel cytoprotective path-
way centered on an AIP-Tom20 recognition that mediates the
mitochondrial import of survivin and thus enables its anti-apo-
ptotic function in vivo (11). Although this mechanism is essen-
tial to maintain productive erythropoiesis and tissue integrity
during development, its exploitation in tumors likely produces
an heightened anti-apoptotic threshold that contributes to dis-
ease progression (7). Conversely, because the AIP-survivin rec-
ognition is specifically associated with inhibition of apoptosis,
molecular antagonists of this pathway may be beneficial to
selectively disable survivin cytoprotection in tumorswhile leav-
ing unscathed its essential functions at cell division in normal
tissues.
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